Table 5. Alteration of anti-PLA2R reactivity in follow-up samples (n = 10).
| Patient | Initial | Remission | Follow-up | ||
| uPCR (g/g) | Anti-PLA2R reactivity | uPCR (g/g) | Anti-PLA2R reactivity | ||
| A | 12.22 | Positive | Yes | 1.73 | Negative |
| B | 4.25 | Positive | Yes | 0 | Negative |
| C | 7.11 | Positive | Yes | 3.24 | Negative |
| D | 5.48 | Positive | Yes | 1.57 | Positive |
| E | 9.86 | Positive | No | 11.43 | Positive |
| F | 13.17 | Positive | No | 4.23 | Positive |
| G | 5.60 | Negative | Yes | 0.23 | Negative |
| H | 5.38 | Negative | Yes | 0.51 | Negative |
| I | 13.20 | Negative | Yes | 2.43 | Negative |
| J | 5.85 | Negative | No | 12.97 | Negative |
Anti-PLA2R, anti-phospholipase A2 receptor antibody; uPCR, urine protein-creatinine ratio.